On the stock market since 2019, it operates in the world of health and science. It has 660 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (1% a year).
If every debt were paid off today, $542.1M would still be left in the vault — a solid cushion for hard times.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 85% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 25% — still a thick cushion, though costs have been eating into it lately.
There is $555.3M in the vault; even if every debt were paid off, $542.1M would remain.
Over the last 12 months, company executives reported 5 buys and 1 sell. Management buying with its own money is usually read as a good sign.
Over the last 3 years, sales fell about 7% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The sales tempo runs behind the sector. Council score: 2/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
On our five-subject report card, INMD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: INMD is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.